NBP NovaBridge Biosciences
Healthcare$1.77-0.56%ClosedMarket Cap: $204.0M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.69
P/S
0.00
EV/EBITDA
-5.53
DCF Value
$0.11
FCF Yield
-0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-3.5%
ROA
-53.4%
ROIC
-94.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $0.00 | NaN% | $-10.4M | $-4.4M | $— | — |
| FY null | $0.00 | NaN% | $-13.5M | $-6.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-9.0M | $-6.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-7.1M | $-5.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-5.3M | $-3.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-13.4M | $-9.1M | $— | — |
| FY null | $0.00 | NaN% | $-375.4M | $-162.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-12.4M | $-20.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-15.0M | $25.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-90.6M | $20.8M | $— | — |
| Q4 2023 | $1.1M | -1687.5% | $-174.9M | $-346.4M | $-4.16 | — |
| FY null | $4.5M | 100.0% | $-511.2M | $-1.47B | $— | — |